Program
JLM019
A development code. Also written as “JLM019 Injection”.
Its studies are mostly in Hodgkin Disease, led by Jecho Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jecho Biopharmaceuticals | 11 open or running | phase 1since May 18, 2026 | May 18, 2026 | Mar 14, 2029phase 1 · NCT07623850 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2026First study: phase 1 study in Hodgkin DiseaseFirst studyNCT07623850 · 115 planned · China
Ahead
- Mar 14, 2029Primary completion: phase 1 study in Hodgkin DiseaseNCT07623850
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623850Hodgkin Disease · China | 1 | Recruiting | Mar 14, 2029 | 115 |
How it is read
Names in the registry
- “JLM019 Injection”, 1 entry
Codes read as this program: JLM019.
Conditions, from the studies’ own filings
- Hodgkin Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.